You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

venetoclax; obinutuzumab; atezolizumab; lymphoma

Showing 1 - 25 of 5,939
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023

Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 30, 2021

CLL Transformation Trial in Italy, Switzerland (Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax

Recruiting
  • CLL Transformation
  • Obinutuzumab 25 MG/ML [Gazyva]
  • +2 more
  • Alessandria, Italy
  • +16 more
Sep 27, 2022

CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive Trial in Atlanta, Johns Creek (Bendamustine, Obinutuzumab, Venetoclax)

Active, not recruiting
  • CCND1 Positive
  • +2 more
  • Atlanta, Georgia
  • +2 more
Nov 2, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Acute Lymphoblastic Leukemia Trial (chidamide, Venetoclax Oral Tablet, Inotuzumab Ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 19, 2023

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

Not yet recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +2 more
  • Biopsy
  • +8 more
  • Duarte, California
    City of Hope Medical Center
May 15, 2023

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

Recruiting
  • Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 20, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Dec 5, 2022

Follicular Lymphoma Trial in Australia (Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous

Recruiting
  • Follicular Lymphoma
  • Obinutuzumab 25 MG/1 ML Intravenous Solution
  • +2 more
  • Ballarat, Victoria, Australia
  • +3 more
Jul 28, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)

Recruiting
  • Lymphoma
  • +3 more
  • obinutuzumab
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Primary CNS Lymphoma Trial in Stuttgart (Venetoclax, Obinutuzumab)

Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Jan 18, 2022

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Trial in Worldwide (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Tucson, Arizona
  • +40 more
Dec 20, 2022

Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)

Not yet recruiting
  • Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 7, 2022

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Non-Hodgkin's Lymphoma Trial in Australia, Italy, United States (Obinutuzumab, Rituximab, Polatuzumab Vedotin)

Completed
  • Non-Hodgkin's Lymphoma
  • Tucson, Arizona
  • +22 more
Aug 5, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Leukemia (SLL)
  • Evanston, Illinois
  • +7 more
Sep 9, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Graz, Austria
  • +5 more
Feb 15, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Japan (Venetoclax, Ibrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Nagoya-shi, Aichi, Japan
  • +19 more
Jan 25, 2023

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021